Top-line results from a Phase III clinical trial of BromSite (bromfenac + DuraSite delivery), from InSite Vision, for the reduction...
InSite Vision Incorporated has announced top-line results from its recently completed Phase III clinical trial of BromSite(ISV-303) for the reduction...
Sun Pharmaceutical Industries Ltd announced that one of its wholly owned subsidiaries has received approval from FDA for its New...
InSite Vision Inc, a company developing ophthalmic products for unmet eye care needs, announced that the FDA has accepted for...
Sun Pharmaceutical Industries Ltd. has announced that one of its subsidiaries has entered into an agreement and plan of merger...
QLT Inc announced that it has entered into a merger agreement with InSite Vision Incorporated pursuant to which QLT will...
American Society Of Haematology (ASH) Congress, 7th - 10th of December 2024, San Diego USA
This trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma.
The FDA has approved on 13 March 2013, Lymphoseek (technetium Tc 99m tilmanocept) Injection, from Navidea Biopharmaceuticals , a radioactive...